Tresiba (insulin degludec) and Lantus (insulin glargine) are brand-name prescription medications. They’re approved by the Food and Drug Administration (FDA) to treat type 1 and type 2 diabetes in ...
Semglee and Insulin Glargine may now be substituted for the reference product Lantus (insulin glargine) at the pharmacy counter. Viatris Inc. and Biocon Biologics have announced the launch of ...
Levemir and Lantus are both long-acting injectable insulins that can be used for long-term management of diabetes. Insulin is a hormone that is naturally produced in the body by the pancreas. It helps ...
Real World Outcome Study of Patients with Type 2 Diabetes Presented at American Diabetes Association 74th Scientific Sessions BRIDGEWATER, N.J., June 14, 2014 /PRNewswire/ -- Sanofi US announced today ...
NEW ORLEANS--As Sanofi’s top-selling Lantus careens toward its first U.S. biosimilar competition in December, the French drugmaker has been developing not only a follow-up diabetes product--the longer ...
Lantus (insulin glargine) is a brand-name subcutaneous injection that’s prescribed for diabetes. It’s used in adults and some children. The cost of the drug with and without insurance can depend on ...
Overview: Insulin glargine is a long-acting insulin used to lower blood sugar levels in people with diabetes. It helps get sugar into your cells, so your body can use it for energy. The most common ...
NEW YORK/PARIS, Jan 31 (Reuters) - French drugmaker Sanofi sued Eli Lilly and Co for alleged patent infringements concerning its top-selling Lantus diabetes treatment, delaying the U.S. company's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback